about
Urinary proteomics and metabolomics studies to monitor bladder health and urological diseasesChallenges for biomarker discovery in body fluids using SELDI-TOF-MS.Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometryAssociation of serum amyloid A protein and peptide fragments with prognosis in renal cancer.Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profilingProteomic analysis of multiple myeloma: current status and future perspectives.The application of SELDI-TOF-MS in clinical diagnosis of cancersEnriched sera protein profiling for detection of non-small cell lung cancer biomarkers.Host cell protein dynamics in the supernatant of a mAb producing CHO cell line.The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer.Identification of a beta-casein-like peptide in breast nipple aspirate fluid that is associated with breast cancer.An integrative multi-platform analysis for discovering biomarkers of osteosarcoma.Protein expression profiles distinguish between experimental invasive pulmonary aspergillosis and Pseudomonas pneumonia.Thyroid tumors: novel insights from proteomic studies.Cancer proteomics.The proteomic toolbox for studying cerebrospinal fluid.Ovarian cancer: biomarker proteomic diagnosis in progress.
P2860
Q26752864-D0B16FD8-A8B7-4598-A5FA-2F4F626EB72FQ33520447-467D061F-A72F-4678-A16D-F5753AC2A829Q33536079-5178DD77-2200-45BD-98F5-D102E80423CBQ33597715-FAA97C67-16CE-46B2-B8FE-F378DE8DCADDQ33769676-568827E7-3F71-4526-BD37-8305C63FDFF8Q33807327-8E77395F-C133-475D-A2D3-E3B36E164828Q33936575-AB643A01-AA1F-49E0-ABEC-9AAAAEF93130Q34022213-C7D1D155-0AF1-4D5D-879F-6CB1C04B4538Q34085446-67F63E4A-F8B8-43D2-B230-0643AAD13CB5Q35261674-6F77C8EB-B01A-43D7-B48F-6A49D240D006Q35418263-F6280F1B-F87E-49D1-9F06-B6D363A8D15FQ36039044-57C3B8D5-3387-4100-9169-FC57AE4A8539Q37214448-7820BBD7-8C87-4DBE-BF2A-2F1FAE15DE5AQ37383763-F996878F-6848-46E9-B27C-09BD9D1773DEQ37579897-C4FE586F-3E4A-4932-A189-B8BFBDDDE323Q37994133-F43AC415-99B1-4616-912C-98C89E5B4A63Q37998531-A7234961-1F72-4DA9-9110-7822DC4FDCC4Q38040333-C6B648E8-6F7D-48D0-BE5C-46B1F82A52BC
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Applications of SELDI-MS technology in oncology
@ast
Applications of SELDI-MS technology in oncology
@en
Applications of SELDI-MS technology in oncology.
@nl
type
label
Applications of SELDI-MS technology in oncology
@ast
Applications of SELDI-MS technology in oncology
@en
Applications of SELDI-MS technology in oncology.
@nl
prefLabel
Applications of SELDI-MS technology in oncology
@ast
Applications of SELDI-MS technology in oncology
@en
Applications of SELDI-MS technology in oncology.
@nl
P2093
P2860
P1476
Applications of SELDI-MS technology in oncology
@en
P2093
K A R Power
L C Whelan
P2860
P304
P356
10.1111/J.1582-4934.2008.00250.X
P577
2008-02-04T00:00:00Z